Mar 19 |
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
|
Mar 6 |
CEL-SCI Corporation Issues Letter to Shareholders
|
Feb 15 |
Cel-Sci GAAP EPS of -$0.14
|
Feb 15 |
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results
|
Feb 13 |
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
|
Feb 12 |
Cel-Sci: Fabulous Story Stock Works To Pass Muster With FDA
|
Feb 9 |
CEL-SCI stock falls as it prices its offering to raise $7.75M
|
Feb 9 |
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
|
Jan 31 |
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®
|
Dec 26 |
Cel-Sci GAAP EPS of -$0.73
|